Nexalin Technology shares rise 11.69% intraday after launching NeuroCare, an AI-driven virtual clinic platform in partnership with UCSD for remote care of Alzheimer's, mood disorders, TBI, and PTSD patients.

Nexalin Technology surged 11.69% intraday, driven by the launch of its AI-powered NeuroCare virtual clinic platform in collaboration with UC San Diego. The platform targets Alzheimer’s, mood disorders, TBI, and PTSD patients via subscription-based remote care. Nexalin, a leader in non-invasive DIFS brain stimulation, integrates its Gen-3 HALO wearable device with NeuroCare for remote monitoring, enhancing patient accessibility and reducing costs.